查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1519457

2024-2032 年按藥物類別、配銷通路和地區分類的 HIV 藥物市場報告

HIV Drugs Market Report by Drug Class, Distribution Channel, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 142 Pages | 商品交期: 2-3個工作天內

價格

IMARC Group年全球愛滋病藥物市場規模達317億美元。由於人們的認知和預防工作不斷增強，愛滋病毒/愛滋病在全球範圍內的流行率不斷上升，以及專注於更有效和更容易獲得的抗逆轉錄病毒療法的各種研究和開發計劃正在進行，推動了該市場的穩定成長。

HIV藥物市場分析：

市場成長與規模：近年來，全球愛滋病毒藥物市場穩定成長。由於愛滋病毒/愛滋病盛行率的增加和治療方案的擴大，預計這一數字將繼續成長。

技術進步：技術進步導致了更有效和更耐受的抗逆轉錄病毒藥物的開發。改進的藥物傳遞機制（例如長效注射劑）提高了治療順從性。此外，遠距醫療和行動健康應用程式正在增強患者管​​理和監控。

產業應用：愛滋病毒藥物市場為全球愛滋病毒/愛滋病患者提供服務。它也可用於預防性治療，包括針對高風險族群的暴露前預防 (PrEP)。此外，該行業與政府、非政府組織和醫療保健提供者合作，以確保獲得藥物和護理。

地理趨勢：撒哈拉以南非洲和亞洲部分地區等高流行地區推動了龐大的需求。由於可以獲得先進的治療方法，北美和歐洲也擁有龐大的市場。此外，拉丁美洲和亞太地區的新興市場也在成長。

競爭格局：市場的特點是競爭激烈，主要參與者專注於創新、併購（M&A）以及擴大全球足跡。這些策略旨在增強產品組合、滿足特定產業需求並應對不斷發展的市場挑戰。

挑戰與機會：挑戰包括需要持續治療、抗藥性以及某些藥物的高成本。機會在於開發更實惠、更容易獲得的藥物、擴大預防工作以及研究潛在的治療方法。

未來展望：愛滋病毒藥物市場的未來充滿希望，正在進行的研究旨在功能性治癒和長效治療。增加獲得藥物和預防方法的機會仍然是全球衛生的優先事項。此外，在技術進步和擴大治療計劃的推動下，市場預計將繼續成長。

HIV藥物市場趨勢：

愛滋病毒/愛滋病的盛行率不斷上升

全球愛滋病毒/愛滋病流行仍然是一個重要的公共衛生議題，截至 2021 年，全球約有 3,800 萬名愛滋病毒感染者。隨著新病例不斷出現，特別是在預防措施有限的地區，對有效治療方案的需求日益增加。愛滋病毒的高傳播率，特別是在撒哈拉以南非洲以及亞洲和東歐的某些地區，需要持續和增加抗逆轉錄病毒治療（ART）的可用性，而這仍然是愛滋病毒治療的基石。

治療方法的進步

近年來，愛滋病毒治療方案取得了重大進展，促進了愛滋病毒藥物市場的成長。結合多種抗逆轉錄病毒藥物的高效抗逆轉錄病毒療法（HAART）的發展徹底改變了愛滋病毒治療。這些進步不僅提高了愛滋病毒藥物的有效性，也減少了副作用，從而提高了患者的依從性和治療效果。整合酶抑制劑等新藥物類別的引入和長效注射劑的開發進一步擴大了治療選擇，滿足不同患者的需求和偏好。

提高患者的意識

提高意識和診斷率對於推動愛滋病毒藥物市場至關重要。公共衛生運動和教育措施提高了人們對愛滋病毒/愛滋病的了解，減少了恥辱並鼓勵更多的人接受檢測。早期和改進的診斷技術也有助於提高愛滋病毒檢出率，從而增加尋求治療的人數。診斷率的上升，加上不斷努力改善愛滋病毒檢測，特別是在流行率高的地區，繼續推動對有效愛滋病毒藥物的需求。

聯合療法日益受到關注

聯合療法已成為愛滋病毒治療的標準，涉及使用多種抗逆轉錄病毒藥物來增強療效並防止抗藥性。固定劑量組合 (FDC) 的開發和批准簡化了治療方案，提高了依從性和患者治療效果。製藥公司越來越注重開發這些聯合療法，與單一療法相比，聯合療法具有多種優勢，包括減少藥物負擔和提高患者依從性。醫療保健提供者和患者對聯合療法的日益偏好是推動愛滋病毒藥物市場的關鍵因素。

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球 HIV 藥物市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 價格分析
  • 市場區隔：依藥品類別
  • 市場區隔：按配銷通路
  • 市場區隔：按地區
  • 市場預測
  • SWOT分析
    • 概述
    • 優勢
    • 弱點
    • 機會
    • 威脅
  • 價值鏈分析
    • 概述
    • 研究與開發
    • 原物料採購
    • 製造業
    • 行銷
    • 分配
    • 最終用途
  • 波特五力分析
    • 概述
    • 買家的議價能力
    • 供應商的議價能力
    • 競爭程度
    • 新進入者的威脅
    • 替代品的威脅

第 6 章：市場區隔：依藥物類別

  • 核苷逆轉錄酶抑制劑
    • 市場走向
    • 市場預測
  • 多類別組合產品
    • 市場走向
    • 市場預測
  • 蛋白酶抑制劑
    • 市場走向
    • 市場預測
  • HIV 整合酶鏈轉移抑制劑
    • 市場走向
    • 市場預測
  • 非核苷逆轉錄酶抑制劑
    • 市場走向
    • 市場預測
  • 進入抑制劑 - CCR5 共受體拮抗劑
    • 市場走向
    • 市場預測
  • 融合抑制劑及其他
    • 市場走向
    • 市場預測

第 7 章：市場區隔：按配銷通路

  • 醫院藥房
    • 市場走向
    • 市場預測
  • 零售藥局
    • 市場走向
    • 市場預測
  • 網路藥局
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 8 章：市場區隔：按地區

  • 北美洲
    • 市場走向
    • 市場預測
  • 歐洲
    • 市場走向
    • 市場預測
  • 亞太地區
    • 市場走向
    • 市場預測
  • 中東和非洲
    • 市場走向
    • 市場預測
  • 拉丁美洲
    • 市場走向
    • 市場預測

第 9 章：HIV 藥物生產流程

  • 產品概述
  • 原料要求
  • 製造流程
  • 關鍵成功因素與風險因素

第 10 章：競爭格局

  • 市場結構
  • 市場區隔：按關鍵參與者
  • 關鍵參與者簡介
    • Boehringer Ingelheim International GmbH
    • Merck & Co., Inc.
    • ViiV Healthcare
    • AbbVie
    • F. Hoffmann-La Roche Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Bristol-Myers Squibb
    • Gilead Sciences, Inc.
    • Johnson & Johnson
    • Cipla Limited
    • Daiichi Sankyo
    • Emcure
    • Hetero Drugs
    • Mylan
Product Code: SR112024A953

The global HIV drugs market size reached US$ 31.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 43.9 Billion by 2032, exhibiting a growth rate (CAGR) of 3.6% during 2024-2032. The market is experiencing steady growth driven by the increasing awareness and prevention efforts, the growing prevalence of HIV/AIDS across the globe, and ongoing various research and development initiatives focused on more effective and accessible antiretroviral therapies.

HIV Drugs Market Analysis:

Market Growth and Size: The global HIV drugs market has witnessed steady growth in recent years. It is expected to continue growing due to the increasing prevalence of HIV/AIDS and the expansion of treatment programs.

Technological Advancements: Technological advancements have led to the development of more potent and tolerable antiretroviral drugs. Improved drug delivery mechanisms, such as long-acting injectables, have increased treatment adherence. Besides, telemedicine and mobile health apps are enhancing patient management and monitoring.

Industry Applications: The HIV drugs market serves patients living with HIV/AIDS worldwide. It also has applications in preventive treatments, including pre-exposure prophylaxis (PrEP) for high-risk populations. Moreover, the industry collaborates with governments, NGOs, and healthcare providers to ensure access to medications and care.

Geographical Trends: High prevalence regions like sub-Saharan Africa and parts of Asia drive significant demand. North America and Europe also have substantial markets due to access to advanced treatments. Besides, emerging markets in Latin America and Asia-Pacific are witnessing growth.

Competitive Landscape: The market is characterized by intense competition with key players focusing on innovation, mergers and acquisitions (M&A), and expanding their global footprint. These strategies aim to enhance product portfolios, meet specific industry needs, and address the challenges of an evolving market.

Challenges and Opportunities: Challenges include the need for continuous treatment, drug resistance, and the high cost of some medications. Opportunities lie in developing more affordable and accessible drugs, expanding prevention efforts, and research into potential cures.

Future Outlook: The future of the HIV drugs market holds promise, with ongoing research aiming for a functional cure and long-acting therapies. Increased access to medications and prevention methods remains a global health priority. Moreover, market growth is expected to continue, driven by technological advancements and expanded treatment programs.

HIV Drugs Market Trends:

The growing prevalence of HIV/AIDS

The global HIV/AIDS epidemic remains a critical public health issue, with approximately 38 million people living with HIV worldwide as of 2021. This increased prevalence directly drives the demand for HIV drugs. As new cases continue to emerge, especially in regions with limited access to preventive measures, the need for effective treatment options intensifies. The high transmission rate of HIV, particularly in sub-Saharan Africa and certain parts of Asia and Eastern Europe, necessitates sustained and increased availability of antiretroviral therapy (ART), which remains the cornerstone of HIV treatment.

Advancements in treatments

Recent years have witnessed significant advancements in HIV treatment regimens, contributing to the growth of the HIV drugs market. The development of highly active antiretroviral therapy (HAART), which combines multiple antiretroviral drugs, has revolutionized HIV treatment. These advancements have not only improved the effectiveness of HIV drugs but also reduced side effects, leading to better patient adherence and outcomes. The introduction of newer drug classes like integrase inhibitors and the development of long-acting injectables have further expanded treatment options, catering to diverse patient needs and preferences.

Increasing awareness among patients

Enhanced awareness and diagnostic rates are pivotal in driving the market for HIV drugs. Public health campaigns and educational initiatives have increased the understanding of HIV/AIDS, reducing stigma and encouraging more people to get tested. Early and improved diagnostic techniques have also contributed to higher detection rates of HIV, subsequently increasing the number of individuals seeking treatment. This rise in diagnosis, coupled with ongoing efforts to improve HIV testing, particularly in regions with high prevalence rates, continues to fuel the demand for effective HIV medications.

Rising focus on combination therapies

Combination therapies have become a standard in HIV treatment, involving the use of multiple antiretroviral drugs to enhance efficacy and prevent drug resistance. The development and approval of fixed-dose combinations (FDCs) have simplified treatment regimens, improving adherence and patient outcomes. Pharmaceutical companies are increasingly focusing on developing these combination therapies, which offer several advantages over monotherapy, including reduced pill burden and improved patient compliance. The growing preference for combination therapies among healthcare providers and patients is a key factor driving the market for HIV drugs.

HIV Drugs Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global and regional levels for 2024-2032. Our report has categorized the market based on drug class and distribution channel.

Breakup by Drug Class:

Nucleoside Reverse Transcriptase Inhibitors

Multi-Class Combination Products

Protease Inhibitors

HIV Integrase Strand Transfer Inhibitors

Non-Nucleoside Reverse Transcriptase Inhibitors

Entry Inhibitors - CCR5 Co-Receptor Antagonist

Fusion Inhibitors and Others

Nucleoside reverse transcriptase inhibitors accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the drug class. This includes nucleoside reverse transcriptase inhibitors, multi-class combination products, protease inhibitors, HIV integrase strand transfer inhibitors, non-nucleoside reverse transcriptase inhibitors, entry inhibitors - CCR5 co-receptor antagonist, fusion inhibitors and others. According to the report, nucleoside reverse transcriptase inhibitors represented the largest segment.

NRTIs, also known as nucleoside analogs, are a crucial class of HIV drugs. They inhibit the action of reverse transcriptase, an enzyme the virus uses to replicate its genetic material. NRTIs are often included as a backbone in HIV treatment regimens due to their effectiveness and safety. They are widely used as a first-line therapy, either alone or in combination with other drug classes, making them the largest segment in the HIV drugs market.

Multi-class combination products refer to antiretroviral therapies that combine drugs from different classes. These combinations are designed to target HIV from multiple angles, reducing the risk of resistance development and increasing treatment efficacy. They offer convenience by simplifying the regimen for patients and are often prescribed when NRTIs alone are insufficient.

Protease inhibitors (PIs) interfere with the protease enzyme, necessary for HIV maturation and replication. PIs are a vital part of combination therapies and have been instrumental in reducing HIV-related deaths. They are used in conjunction with other drug classes to suppress viral replication effectively.

Integrase strand transfer inhibitors (INSTIs) block the integration of viral genetic material into the host cell's DNA, preventing viral replication. INSTIs have gained prominence due to their potent antiviral activity and favorable side-effect profiles. They are commonly used in first-line regimens and in treatment-experienced patients.

NNRTIs are another class of HIV drugs that target reverse transcriptase but do so differently from NRTIs. They bind to the enzyme and inhibit its activity. NNRTIs are often part of combination therapies and are especially useful in cases where resistance to other drug classes has developed.

CCR5 co-receptor antagonists block the CCR5 receptor on the surface of immune cells, preventing HIV from entering and infecting these cells. They are typically used in patients who are CCR5-tropic, meaning their virus uses the CCR5 co-receptor for entry.

Fusion inhibitors work by preventing the virus from fusing with the host cell membrane, thus inhibiting viral entry. This class of drugs is less commonly used than others due to their complex administration (usually by injection).

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

Hospital pharmacies holds the largest share in the industry

A detailed breakup and analysis of the market based on the distribution channel have also been provided in the report. This includes hospital pharmacies, retail pharmacies, online pharmacies and others. According to the report, hospital pharmacies accounted for the largest market share.

Hospital pharmacies constitute the largest segment in the HIV drugs market, primarily due to their role as essential providers of antiretroviral therapies to inpatients and outpatients living with HIV/AIDS. These pharmacies operate within healthcare institutions, including public and private hospitals, clinics, and specialty HIV treatment centers. They offer a wide range of HIV medications, ensuring access to the latest antiretroviral therapies for patients. Hospital pharmacies play a crucial role in medication management, counseling, and monitoring, contributing significantly to patient adherence and treatment outcomes. With a direct link to healthcare providers, hospital pharmacies are pivotal in the comprehensive care and management of HIV/AIDS patients.

Retail pharmacies, including independent drugstores and chain pharmacies, form another vital segment in the HIV drugs market. They serve as accessible points of care for individuals seeking prescription medications, including antiretroviral drugs. Retail pharmacies provide convenience and privacy for patients picking up their HIV medications. They play a critical role in supporting medication adherence through counseling and refill reminders. The retail segment is especially important for patients in urban and suburban areas who may not access hospital-based care regularly.

Online pharmacies have gained prominence as a convenient and discrete source of HIV medications. This segment caters to individuals who prefer the convenience of ordering their antiretroviral drugs online and having them delivered to their doorstep. Online pharmacies offer a wide selection of HIV medications, often at competitive prices. They may also provide telemedicine services, enabling patients to consult with healthcare professionals remotely. The online pharmacy segment has seen significant growth, particularly in regions with robust e-commerce infrastructure, and it serves as an option for individuals who face barriers to traditional pharmacy access.

Breakup by Region:

North America

Europe

Asia Pacific

Middle East and Africa

Latin America

North America leads the market, accounting for the largest HIV drugs market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America dominates the global HIV drugs market due to its well-developed healthcare infrastructure, high awareness about HIV/AIDS, and access to advanced antiretroviral therapies. The region is characterized by extensive research and development activities, a large patient population, and significant government funding for HIV/AIDS programs. Furthermore, the presence of major pharmaceutical companies in North America contributes to the market's growth. The focus here is on innovative treatments, combination therapies, and efforts to reduce new infections through comprehensive prevention strategies.

Europe is a substantial market for HIV drugs, characterized by a well-regulated healthcare system and access to state-of-the-art treatments. The region has made progress in reducing HIV transmission rates, but it continues to face challenges related to stigma and late diagnosis. The market in Europe is driven by increasing awareness, comprehensive healthcare coverage, and collaborations between healthcare providers and pharmaceutical companies to improve patient outcomes. Additionally, research into long-acting therapies and preventive measures like PrEP contributes to the market's development.

The Asia Pacific region is witnessing rapid growth in the HIV drugs market due to its large and diverse population, including many individuals living with HIV. This segment faces unique challenges, such as varying healthcare infrastructure, economic disparities, and culturally diverse populations. Increased efforts to expand access to treatment, raise awareness, and reduce new infections are driving market growth. Generic medications and government initiatives to combat HIV/AIDS play a significant role in the Asia Pacific market. Moreover, collaborations with international organizations and NGOs are enhancing the region's response to the HIV epidemic.

Latin America has a growing HIV drugs market, driven by the expanding healthcare infrastructure and increased access to treatment and prevention programs. The region faces challenges related to inequality and limited access to healthcare services in some areas. However, initiatives to improve healthcare coverage, raise awareness, and expand access to antiretroviral therapies are driving market growth. Collaboration between governments, pharmaceutical companies, and non-profit organizations is critical to addressing the HIV/AIDS epidemic in Latin America.

The Middle East and Africa represent a diverse and challenging market for HIV drugs. While access to treatment has improved in some countries, significant disparities persist due to economic and healthcare infrastructure differences. The region faces cultural and social stigma related to HIV/AIDS, which can hinder diagnosis and treatment. Nonetheless, efforts to expand access to medications, increase awareness, and promote preventive measures are ongoing. Partnerships with international organizations and global health initiatives are crucial in addressing the unique challenges in the Middle East and Africa.

Leading Key Players in the HIV Drugs Industry:

Key players in the global HIV drugs market are actively engaged in several strategic initiatives. They are focusing on research and development to innovate and improve existing antiretroviral therapies, aiming for more convenient dosing regimens, fewer side effects, and enhanced treatment outcomes. These companies are also expanding their product portfolios by developing new drugs and combination therapies. Additionally, they are collaborating with governments, NGOs, and healthcare providers to increase access to HIV medications in resource-limited regions and to implement preventive measures. Furthermore, these pharmaceutical giants are investing in awareness campaigns and education to reduce HIV stigma and promote early diagnosis and treatment.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Boehringer Ingelheim International GmbH

Merck & Co., Inc.

ViiV Healthcare

AbbVie

F. Hoffmann-La Roche Ltd.

Teva Pharmaceutical Industries Ltd.

Bristol-Myers Squibb Gilead Sciences, Inc.

Johnson & Johnson

Cipla Limited

Daiichi Sankyo

Emcure Pharmaceuticals

Hetero Drugs

Mylan N.V

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Latest News:

2021: Merc received approval from the U.S. Food and Drug Administration (FDA) for its new antiretroviral drug, Isentress HD, which offers improved dosing convenience for patients. The introduction of ISENTRESS HD reflects Merck's commitment to innovation in HIV therapy, offering a broader range of treatment options to fit the individual needs and lifestyles of people living with HIV. The price of ISENTRESS HD is set to be the same as the twice-daily ISENTRESS, and it was anticipated to be available in pharmacies approximately four weeks following the approval announcement.

June 2022: Cipla Ltd. and its partner Drugs for Neglected Diseases Initiative (DNDi) reported the availability of a 4-in-1 antiretroviral medication for younger children. This innovative treatment has been approved by the South African Health Products Regulatory Authority (SAHPRA) and is specifically designed for infants and young children living with HIV.

In 2021: Johnson & Johnson has also been actively involved in the development of HIV drugs. In 2021, the company received FDA approval for its new antiretroviral drug, Rekambys, which is a long-acting injectable treatment option for HIV-1 infection in certain patients.

Key Questions Answered in This Report

  • 1. What was the size of the global HIV drugs market in 2023?
  • 2. What is the expected growth rate of the global HIV drugs market during 2024-2032?
  • 3. What has been the impact of COVID-19 on the global HIV drugs market?
  • 4. What are the key factors driving the global HIV drugs market?
  • 5. What is the breakup of the global HIV drugs market based on the drug class?
  • 6. What is the breakup of the global HIV drugs market based on the distribution channel?
  • 7. What are the key regions in the global HIV drugs market?
  • 8. Who are the key players/companies in the global HIV drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global HIV Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Price Analysis
  • 5.5 Market Breakup by Drug Class
  • 5.6 Market Breakup by Distribution Channel
  • 5.7 Market Breakup by Region
  • 5.8 Market Forecast
  • 5.9 SWOT Analysis
    • 5.9.1 Overview
    • 5.9.2 Strengths
    • 5.9.3 Weaknesses
    • 5.9.4 Opportunities
    • 5.9.5 Threats
  • 5.10 Value Chain Analysis
    • 5.10.1 Overview
    • 5.10.2 Research and Development
    • 5.10.3 Raw Material Procurement
    • 5.10.4 Manufacturing
    • 5.10.5 Marketing
    • 5.10.6 Distribution
    • 5.10.7 End-Use
  • 5.11 Porters Five Forces Analysis
    • 5.11.1 Overview
    • 5.11.2 Bargaining Power of Buyers
    • 5.11.3 Bargaining Power of Suppliers
    • 5.11.4 Degree of Competition
    • 5.11.5 Threat of New Entrants
    • 5.11.6 Threat of Substitutes

6 Market Breakup by Drug Class

  • 6.1 Nucleoside Reverse Transcriptase Inhibitors
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Multi-Class Combination Products
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Protease Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 HIV Integrase Strand Transfer Inhibitors
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Non-Nucleoside Reverse Transcriptase Inhibitors
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Entry Inhibitors - CCR5 Co-Receptor Antagonist
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Fusion Inhibitors and Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Hospital Pharmacies
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Retail Pharmacies
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Online Pharmacies
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Europe
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Asia Pacific
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Middle East and Africa
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Latin America
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 HIV Drugs Manufacturing Process

  • 9.1 Product Overview
  • 9.2 Raw Material Requirements
  • 9.3 Manufacturing Process
  • 9.4 Key Success and Risk Factors

10 Competitive Landscape

  • 10.1 Market Structure
  • 10.2 Market Breakup by Key Players
  • 10.3 Profiles of Key Players
    • 10.3.1 Boehringer Ingelheim International GmbH
    • 10.3.2 Merck & Co., Inc.
    • 10.3.3 ViiV Healthcare
    • 10.3.4 AbbVie
    • 10.3.5 F. Hoffmann-La Roche Ltd.
    • 10.3.6 Teva Pharmaceutical Industries Ltd.
    • 10.3.7 Bristol-Myers Squibb
    • 10.3.8 Gilead Sciences, Inc.
    • 10.3.9 Johnson & Johnson
    • 10.3.10 Cipla Limited
    • 10.3.11 Daiichi Sankyo
    • 10.3.12 Emcure
    • 10.3.13 Hetero Drugs
    • 10.3.14 Mylan

List of Figures

  • Figure 1: Global: HIV Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: HIV Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: HIV Drugs Market: Breakup by Drug Class (in %), 2023
  • Figure 4: Global: HIV Drugs Market: Breakup by Distribution Channel (in %), 2023
  • Figure 5: Global: HIV Drugs Market: Breakup by Region (in %), 2023
  • Figure 6: Global: HIV Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 7: Global: HIV Drugs Industry: SWOT Analysis
  • Figure 8: Global: HIV Drugs Industry: Value Chain Analysis
  • Figure 9: Global: HIV Drugs Industry: Porter's Five Forces Analysis
  • Figure 10: Global: HIV Drugs (Nucleoside Reverse Transcriptase Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: HIV Drugs (Nucleoside Reverse Transcriptase Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: HIV Drugs (Multi-Class Combination Products) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: HIV Drugs (Multi-Class Combination Products) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: HIV Drugs (Protease Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: HIV Drugs (Protease Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: HIV Drugs (HIV Integrase Strand Transfer Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: HIV Drugs (HIV Integrase Strand Transfer Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: HIV Drugs (Non-Nucleoside Reverse Transcriptase Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: HIV Drugs (Non-Nucleoside Reverse Transcriptase Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: HIV Drugs (Entry Inhibitors - CCR5 Co-Receptor Antagonist) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: HIV Drugs (Entry Inhibitors - CCR5 Co-Receptor Antagonist) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: HIV Drugs (Fusion Inhibitors and Others) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: HIV Drugs (Fusion Inhibitors and Others) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: HIV Drugs Market: Sales through Hospital Pharmacies (in Million US$), 2018 & 2023
  • Figure 25: Global: HIV Drugs Market Forecast: Sales through Hospital Pharmacies (in Million US$), 2024-2032
  • Figure 26: Global: HIV Drugs Market: Sales through Retail Pharmacies (in Million US$), 2018 & 2023
  • Figure 27: Global: HIV Drugs Market Forecast: Sales through Retail Pharmacies (in Million US$), 2024-2032
  • Figure 28: Global: HIV Drugs Market: Sales through Online Pharmacies (in Million US$), 2018 & 2023
  • Figure 29: Global: HIV Drugs Market Forecast: Sales through Online Pharmacies (in Million US$), 2024-2032
  • Figure 30: Global: HIV Drugs Market: Sales through Other Distribution Channels (in Million US$), 2018 & 2023
  • Figure 31: Global: HIV Drugs Market Forecast: Sales through Other Distribution Channels (in Million US$), 2024-2032
  • Figure 32: North America: HIV Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: North America: HIV Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Europe: HIV Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Europe: HIV Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Asia Pacific: HIV Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Asia Pacific: HIV Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Middle East and Africa: HIV Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Middle East and Africa: HIV Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Latin America: HIV Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Latin America: HIV Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: HIV Drugs Manufacturing: Detailed Process Flow
  • Figure 43: Global: HIV Drugs Market: Breakup by Key Players (in %)

List of Tables

  • Table 1: Global: HIV Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: HIV Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 3: Global: HIV Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 4: Global: HIV Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 5: HIV Drugs Manufacturing: Raw Material Requirements
  • Table 6: Global: HIV Drugs Market: Competitive Structure
  • Table 7: Global: HIV Drugs Market: Key Players